Study of interleukins 1, 3, 4, 5 before and after Surgery of patients with nasal polyposis

2003 ◽  
Vol 129 (2) ◽  
pp. P214 ◽  
Author(s):  
R Voegels
Keyword(s):  
Nasal Polyposis ◽  
Before And After

Comparison of montelukast and mometasone furoate in the prevention of recurrent nasal polyps

2011 ◽  
Vol 6 (1) ◽  
pp. 5-10 ◽  
Author(s):  
Erkan Vuralkan ◽  
Cem Saka ◽  
Istemihan Akin ◽  
Sema Hucumenoglu ◽  
Binnur Uzmez Unal ◽  
...  
Keyword(s):  
Recurrence Rate ◽  
Nasal Spray ◽  
Peripheral Blood ◽  
Nasal Polyposis ◽  
Mometasone Furoate ◽  
Significant Difference ◽  
Before And After ◽  
Group A ◽  
Group B ◽  
Snot 22

Background: The aim of our study was to compare the effects of montelukast and mometasone furoate nasal spray on the postoperative course of patients with nasal polyposis. Patients and methods: Fifty patients diagnosed with nasal polyposis between March 2006 and August 2007 were included in the study. All patients underwent bilateral endoscopic sphenoethmoidectomy and were randomized postoperatively into two groups. Group A ( n = 25) received 10 mg montelukast per day and group B ( n = 25) received 400 µg mometasone furoate nasal spray twice daily. All patients were followed up for 6 months. Sino-Nasal Outcome Test (SNOT)-22 scores, polyp grades, computerized tomography (CT) scores (Lund–Mackay), eosinophils in peripheral blood and polyp tissue were evaluated before and after surgery. Results: There was a significant reduction in SNOT-22 scores in both groups throughout the study period. There was a significant difference in the recurrence rate between both groups with a marginal advantage of mometasone furoate nasal spray. Eosinophils in peripheral blood were found to be effective on the recurrence rate ( p < 0.05). Conclusions: In conclusion, both drugs seem to have a complementary action and further studies are needed to determine which patients should receive which treatment.

Efficacy of Montelukast in the Treatment of Nasal Polyposis

2005 ◽  
Vol 114 (12) ◽  
pp. 941-945 ◽  
Author(s):  
David A. Kieff ◽  
Nicolas Y. Busaba
Keyword(s):  
Symptom Score ◽  
Nasal Polyposis ◽  
Winter Season ◽  
Montelukast Sodium ◽  
Intranasal Steroids ◽  
Symptom Scores ◽  
Before And After ◽  
Perennial Rhinitis ◽  
Seasonal Allergies ◽  
Eosinophil Counts

Objectives: Twenty-four consecutive patients with symptomatic nasal polyposis and nonallergic or perennial rhinitis who were undergoing chronic nasal steroid therapy were prospectively evaluated for response to adjunctive oral montelukast sodium therapy. Methods: The patients were undergoing daily intranasal steroid sprays for a minimum of 6 months before being started on montelukast sodium 10 mg by mouth per day for 3 months while intranasal steroids were continued. The patients were given a validated symptom score survey at the start and end of therapy, with a lower score indicating fewer symptoms. The nasal polyps were submitted to biopsy before and after treatment to determine their degree of eosinophilia. Eosinophilia was graded in a blinded fashion by an independent pathologist on a scale of 0 to 3, with 3 being severe. Patients with seasonal allergies were excluded, and the studied patients were treated during the winter season to avoid confounding by potential seasonal allergic responses. Results: The patients tended to improve on montelukast therapy in terms of their symptom scores and polyp eosinophil counts. The symptoms improved in 17 patients (71%) and remained the same or worsened in 7 patients (29%). The symptom score for the group improved from a pretreatment value of 33.4 (SD, 7.73) to a posttreatment value of 23.3 (SD, 13.73; p < .001). In addition, the eosinophilia score improved from 2.3 (SD, 0.68) to 1.5 (SD, 0.82; p < .01). The improvement was most noticeable in the patients with perennial allergies. Conclusions: These results suggest that montelukast appears to be beneficial for some patients with nasal polyposis. Patients with perennial allergies and nasal polyposis seem more likely to respond to the treatment than those with nonallergic nasal polyposis.

scholarly journals Azithromycin for the Treatment of Eosinophilic Nasal Polyposis: Clinical and Histologic Analysis

2016 ◽  
Vol 7 (2) ◽  
pp. ar.2016.7.0160
Author(s):  
Isamara Simas de Oliveira ◽  
Paulo Fernando Tormin Borges Crosara ◽  
Geovanni Dantas Cassali ◽  
Diego Carlos dos Reis ◽  
Danilo Santana Rodrigues ◽  
...  
Keyword(s):  
Nasal Polyposis ◽  
Therapeutic Option ◽  
Three Dimensional ◽  
Absolute Number ◽  
Prolonged Treatment ◽  
Promising Tool ◽  
Airway Diseases ◽  
Before And After ◽  
Inflammatory Pattern ◽  
Aspirin Intolerance

Introduction Macrolides used as immunomodulators are a promising tool for chronic inflammatory airway diseases. Eosinophilic nasal polyposis (ENP) is still considered a disease that is difficult to control with the currently standardized treatments. Objectives To evaluate prolonged treatment with low-dose azithromycin for ENP based on clinical and histopathologic variables. Methods The present investigation was a self-paired case study of 33 patients with ENP. A comparison was performed between patients before and after treatment with azithromycin for 8 weeks. The patients were subjected to clinical examinations, staging (three-dimensional imaging by endoscopy), application of the questionnaire, and biopsy of nasal polyps at the beginning and at the end of the treatment. Results The treatment yielded a clinical improvement regarding the two variables studied: polyposis staging (69.7%) and questionnaire (57.6%). We did not find significant differences in the inflammatory pattern and in the percentage or absolute number of eosinophils per field between samples obtained before and after the treatment (p > 0.05). There was no difference between the answers obtained from groups with and without asthma and/or aspirin intolerance (p > 0.3). The patients with advanced initial staging exhibited lower subjective improvement index and staging reduction (p = 0.031 and p = 0.012, respectively). Conclusion Based on this study, azithromycin may be considered as another therapeutic option for ENP. However, further studies are necessary to define the real mechanism of action involved.

Expression of Interleukins in Patients with Nasal Polyposis

2005 ◽  
Vol 132 (4) ◽  
pp. 613-619 ◽  
Author(s):  
Richard Louis Voegels ◽  
Francini Grecco Melo De Pádua
Keyword(s):  
Surgical Treatment ◽  
Nasal Obstruction ◽  
Study Design ◽  
Immunosorbent Assay ◽  
Nasal Polyposis ◽  
Clinical Symptoms ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Fourth Decade ◽  
Before And After

OBJECTIVE: To correlate the levels of interleukins 1 β, 3, 4, and 5 before and after surgery and compare the levels between patients with and without recurrence of nasal polyposis. STUDY DESIGN AND SETTING: Thirty-nine patients with NP were selected, 13 of them allergic and 26 nonallergic. A control group of 11 individuals was also studied. The concentrations of interleukins were measured by enzyme-linked immunosorbent assay. RESULTS: There was a higher incidence of NP after the fourth decade of life and among men. The clinical symptoms were similar in both groups of patients with nasal polyposis and characterized by nasal obstruction and anosmia. A significant reduction of all interleukins studied was observed after surgical treatment. CONCLUSION: Levels of interleukins 1β, 3, 4, and 5 were significantly reduced after surgery and the levels of interleukins 1β and 5 were significantly lower in patients without recurrence of nasal polyposis after surgery when compared to those with recurrence.

Evaluation of combined medical and surgical treatment in nasal polyposis – III. Correlation between symptoms and CT scores before and after surgery for nasal polyposis

2008 ◽  
Vol 128 (3) ◽  
pp. 318-323 ◽  
Author(s):  
>Pierre Bonfils ◽  
Laurent Tavernier ◽  
Hesham Abdel Rahman ◽  
Michael Mimoun ◽  
David Malinvaud
Keyword(s):  
Surgical Treatment ◽  
Nasal Polyposis ◽  
Before And After

Acoustic rhinometry used as a method to monitor the effect of intramuscular injection of steroid in the treatment of nasal polyps

1991 ◽  
Vol 105 (3) ◽  
pp. 178-180 ◽  
Author(s):  
O. Elbrønd ◽  
J. U. Feeding ◽  
K. M. Gustavsen
Keyword(s):  
Nasal Cavity ◽  
Nasal Polyps ◽  
Nasal Polyposis ◽  
Peak Flow ◽  
Systemic Treatment ◽  
Acoustic Rhinometry ◽  
Self Assessment ◽  
Cross Sectional ◽  
Before And After ◽  
Recurrent Nasal Polyposis

AbstractAcoustic rhinometry is a new method which describes the geometry of the nasal cavity and the epipharynx. The method, based on the reflection of an acoustic signal entered into the nasal cavity, can be used to evaluate the cross-sectional area of the nasal cavity asa function of distance from the nostril. The method has, together with nasal expiratory peak flow (NPF) and nasal index based upon a self assessment score, been used to evaluate, in an objective and dynamic way, the effect of systemic treatment of nasal polyps with steroids in a series of eight patients with recurrent nasal polyposis. The study shows a significant relationship between these three parameters before and after systemic treatment of nasal polyps with steroids. It is concluded that in this study acoustic rhinometry had an accurate and objective method for measuring the geometry of the nasal cavity before and after treatment for processes which block the nasal cavity.

scholarly journals Immunomodulatory and Clinical Effects of Long-Term Low-Dose Macrolide Treatment of Chronic Rhinosinusitis with Nasal Polyposis

2011 ◽  
Vol 30 (1) ◽  
pp. 45-50 ◽  
Author(s):  
Aleksandar Perić ◽  
Danilo Vojvodić ◽  
Nenad Baletić ◽  
Aneta Perić ◽  
Olivera Miljanović
Keyword(s):  
Chronic Rhinosinusitis ◽  
Nasal Polyposis ◽  
Low Dose ◽  
Nasal Symptom ◽  
Clinical Effects ◽  
Flow Cytometric Method ◽  
Tnf Α ◽  
Before And After ◽  
Nasal Fluid

Immunomodulatory and Clinical Effects of Long-Term Low-Dose Macrolide Treatment of Chronic Rhinosinusitis with Nasal PolyposisImmunomodulatory treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) by macrolide antibiotics represents a challenging alternative to conventional therapy and surgery, still being at the very beginning. Immune and inflammatory processes in nasal and paranasal sinus mucosa, crucial in the etiopathogenesis of nasal polyps (NPs) are reflected in levels of various local mediators, found both in mucosa and nasal fluid. In this prospective study, we assessed the immunomodulatory and clinical effects of longterm low-dose oral macrolide treatment in the management of CRSwNP. Twenty-two (n = 22) nonasthmatic, nonallergic patients with CRSwNP were administered clarithromycin (CAM) 500 mg/day single oral dose for eight weeks. We measured the levels of proinflammatory cytokines TNF-α, TNF-β, and IL-1β, Th1 cytokines IL-2, IL-12, and IFN-γ, Th2 cytokines IL-4, IL-5, IL-6, and IL-10, and chemokine IL-8 in the nasal fluid samples, before and after treatment, using a flow cytometric method. We also scored each of the 22 patients before and after therapy according to Tsicopoulos' global nasal symptom score and Malm's endoscopic score. Following treatment, we found significantly reduced levels of IL-8 (p<0.01) and TNF-α (p<0.01) in nasal secretions. Macrolide therapy decreased the size of polyps in 45.45% of the patients. We concluded that long-term low-dose treatment with CAM was effective in the management of CRSwNP. We suggest that macrolides can be an alternative to topical and systemic corticosteroids in the management of CRSwNP.

Effect of long-term, low-dose clarithromycin on T helper 2 cytokines, eosinophilic cationic protein and the ‘regulated on activation, normal T cell expressed and secreted’ chemokine in the nasal secretions of patients with nasal polyposis

2012 ◽  
Vol 126 (5) ◽  
pp. 495-502 ◽  
Author(s):  
A Perić ◽  
D Vojvodić ◽  
S Matković-Jožin
Keyword(s):  
T Cell ◽  
Nasal Polyposis ◽  
Interleukin 4 ◽  
T Helper ◽  
Eosinophilic Cationic Protein ◽  
Polyp Size ◽  
Cationic Protein ◽  
T Helper 2 ◽  
Cytokines And Chemokines ◽  
Before And After

AbstractBackground:Little is known about the effects of macrolides on the cytokines and chemokines that modulate the function of eosinophils in nasal polyposis.Methods:Twenty-two non-allergic and 18 allergic patients with nasal polyps were administered clarithromycin 500 mg/day (single oral dose) for eight weeks. We measured the nasal secretion levels of the T helper 2 (also known as Th2) cytokines interleukin 4, 5 and 6, the ‘regulated on activation, normal T cell expressed and secreted’ (also known as RANTES) chemokine, and the eosinophilic cationic protein, before and after treatment.Results:After clarithromycin treatment, we found reduced levels of the ‘regulated on activation, normal T cell expressed and secreted’ chemokine in samples from both non-allergic and allergic patients (p < 0.05). Clarithromycin treatment decreased the levels of eosinophilic cationic protein only in non-allergic patients (p < 0.05), and decreased the level of interleukin 6 only in allergic patients (p < 0.05). Decreased levels of the ‘regulated on activation, normal T cell expressed and secreted’ chemokine were associated with a reduction in polyp size both in non-allergic and allergic patients.Conclusion:Clarithromycin has a strong anti-inflammatory effect in nasal polyposis, but has different immunomodulatory effects in allergic and non-allergic nasal polyposis patients.

scholarly journals The Effect of Aspirin on Moderate to Severe Asthmatic Patients with Aspirin Hypersensitivity, Chronic Rhinosinusitis, and Nasal Polyposis.

2021 ◽  
Author(s):  
Saba Arshi ◽  
Sepideh Darougar ◽  
Mohammad Nabavi ◽  
Mohammad Hassan Bemanian ◽  
Morteza Fallahpour ◽  
...  
Keyword(s):  
Chronic Rhinosinusitis ◽  
Asthma Control ◽  
Severe Asthma ◽  
Nasal Polyposis ◽  
Clinical Findings ◽  
Act Scores ◽  
Asthma Control Test ◽  
Asthmatic Patients ◽  
Before And After ◽  
Aspirin Hypersensitivity

Asthmatic patients may have aspirin-exacerbated respiratory disease and experience acute dyspnea and nasal symptoms within 3 hours after the ingestion of aspirin. This study aimed to evaluate the effect and outcome of daily low-dose aspirin in the treatment of moderate to severe asthma in patients with concomitant aspirin hypersensitivity and chronic rhinosinusitis with nasal polyposis (CRSwNP). This clinical trial was conducted from February 2014 to February 2015 on 46 adult patients with moderate to severe asthma accompanied by CRSwNP. Patients with a positive aspirin challenge were blindly randomized in three groups receiving placebo/day (A); aspirin 100 mg/day (B); and aspirin 325mg/day (C), respectively. Clinical findings, FEV1 and ACT scores were recorded and compared before, during, and after treatment for 6 months (IRCT2015061521970N2). Of 46 participants at baseline, 30 patients completed this 6-month trial study. The level of asthma control was significant; based on Asthma Control Test (ACT) when comparing the results in groups A and C and also groups B and C, but it was not significant when comparing ACT scores between groups A and B. FEV1 before and after treatment was significant when comparing groups A and B, groups A and C, and groups B and C. To conclude, aspirin desensitization with a daily dose of 325 mg aspirin resulted in the improvement of long-term control of asthma. A daily aspirin dose of 100 mg was not associated with such an increase in ACT score.

Sign in / Sign up

Export Citation Format

Share Document